VERICEL CORPORATION

VCEL ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011
Revenue $90.9M $63.9M $54.4M $51.2M $28.8M $19.0K $21.0K $18.0K
Cost of Revenue $32.2M $30.4M $28.3M $26.5M $17.3M $4.0K $6.0K $4.0K
Gross Profit $58.7M $33.6M $26.1M $24.7M $11.5M $15.0K $15.0K $14.0K
Gross Margin 64.6% 52.5% 47.9% 48.3% 39.9% 78.9% 71.4% 77.8%
Operating Expenses
Research & Development $13.6M $12.9M $15.3M $18.9M $21.3M $15.1M $26.0M $21.3M
SG&A Expense $49.0M $35.6M $27.4M $22.5M $13.8M $5.9M $7.8M $7.7M
Operating Income $-3.9M $-15.0M $-19.2M $-16.7M $-23.5M $-21.0M $-33.8M $-29.0M
Operating Margin -4.3% -23.4% -35.4% -32.6% -81.7% -110,336.8% -160,761.9% -161,333.3%
Interest Expense $31.0K $92.0K $15.0K $9.0K $6.0K $11.0K $12.0K $10.0K
Pretax Income $-8.1M $-17.3M $-19.6M $-16.3M $-19.9M $-15.6M $-29.5M $-19.7M
Income Tax Expense $0 $0 $0 $0 $0 $0
Net Income $-8.1M $-17.3M $-19.6M $-16.3M $-19.9M $-15.6M $-29.5M $-19.7M
Net Margin -9.0% -27.0% -36.0% -31.9% -69.2% -82,221.1% -140,352.4% -109,266.7%
EPS (Basic) $-0.20 $-0.52 $-1.18 $-0.97 $-2.23 $-6.95 $-16.25 $-10.18
EPS (Diluted) $-0.20 $-0.52 $-1.18 $-0.97 $-2.23 $-6.95 $-16.25 $-10.18
Shares Outstanding (Basic) 40.2M 35.9M 31.6M 23.8M 23.8M 4.7M 2.2M 38.6M
Shares Outstanding (Diluted) 40.2M 35.9M 31.6M 23.8M 23.8M 4.7M 2.2M 38.6M
Dividends Per Share
← Newer Page 2 of 3 Older →